| Title |
Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity
|
|---|---|
| Published in |
Annals of Hematology, January 2017
|
| DOI | 10.1007/s00277-017-2931-z |
| Pubmed ID | |
| Authors |
Thomas S. Y. Chan, Tsan-Hei Luk, June S. M. Lau, Pek-Lan Khong, Yok-Lam Kwong |
| Abstract |
Five patients with refractory/relapsed classical Hodgkin lymphoma (cHL), four having failed multiple lines of chemotherapy and brentuximab vedotin, were treated with low-dose pembrolizumab (median dose 100 mg, range: 100-200 mg, every 3 weeks). Complete response (CR) was achieved in four patients (80%), after a median cumulative dose of merely 495 (300-800) milligrams. Three CR patients have continued to receive pembrolizumab for a median of 16 (14-25) cycles, remaining in CR for a median of 18 (9-18) months. One CR patient underwent autologous hematopoietic stem cell transplantation and has remained in CR for 9 months. Partial response (PR) was achieved in one patient (20%), after a cumulative dose of 400 mg. The overall response rate was therefore 100% (CR: 80%; PR: 20%). Toxicity was virtually absent, with only grade 1 diarrhea and eczema each observed in one patient. Low-dose pembrolizumab was highly efficacious, achieving responses with minimal toxicity and at much lower costs. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 20% |
| United Kingdom | 1 | 20% |
| United States | 1 | 20% |
| Australia | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 60% |
| Members of the public | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 21% |
| Student > Master | 7 | 18% |
| Other | 5 | 13% |
| Professor > Associate Professor | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 4 | 11% |
| Unknown | 9 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Agricultural and Biological Sciences | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Unspecified | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 10 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2022.
All research outputs
#5,592,945
of 23,114,117 outputs
Outputs from Annals of Hematology
#287
of 2,206 outputs
Outputs of similar age
#104,196
of 420,858 outputs
Outputs of similar age from Annals of Hematology
#2
of 23 outputs
Altmetric has tracked 23,114,117 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,206 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,858 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.